CSPC Pharmaceutical Group Ltd. has announced that its recombinant fully human anti-βKlotho monoclonal antibody drug, JMT202, has received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States. This drug, an FGFR1c/βKlotho receptor agonist, is designed to regulate glycolipid metabolism and has potential applications in treating metabolism-related diseases such as dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes, and obesity. The clinical trial will focus on hypertriglyceridemia $(HTG.UK)$. JMT202 has previously obtained approval from the National Medical Products Administration of China and is undergoing trials in China. Preclinical studies have shown that the drug has a favorable safety profile and can significantly reduce triglyceride levels, suggesting promising clinical development potential.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。